
NEJM This Week — July 17, 2025
NEJM This Week
00:00
Intro
This chapter reviews recent advancements in treating gastric and gastroesophageal junction cancer through a phase 3 trial. It highlights how the combination of Dervalumab with FLOT chemotherapy enhanced event-free survival, suggesting the integration of immunotherapy in treating these cancers.
Transcript
Play full episode